Carrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable CNLC Stage IIa/IIb (BCLC Stage B) Hepatocellular Carcinoma: Randomized, Open, Parallel Control, Phase 2/3 Sequential Research
Latest Information Update: 27 Jun 2023
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 06 Jun 2023 Primary Results (n=119; of phase II stage) assessing the efficacy and safety of camrelizumab plus apatinib (C+A) as a perioperative regimen in resectable HCC at intermediate-high risk of recurrence presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 Apr 2021 Planned number of patients changed from 514 to 290.
- 25 Apr 2021 Planned End Date changed from 30 Dec 2024 to 1 Mar 2026.